Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Laboratorios Farmaceuticos Rovi's EV-to-EBIT for today is
Laboratorios Farmaceuticos Rovi's current Enterprise Value is €2,988.9 Mil.
Laboratorios Farmaceuticos Rovi's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €175.4 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Laboratorios Farmaceuticos Rovi's EV-to-EBITDA for today is:
Laboratorios Farmaceuticos Rovi's current Enterprise Value is €2,988.9 Mil.
Laboratorios Farmaceuticos Rovi's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €206.7 Mil.
Laboratorios Farmaceuticos Rovi's current Enterprise Value is €2,988.9 Mil.
Laboratorios Farmaceuticos Rovi's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €741.1 Mil.
Laboratorios Farmaceuticos Rovi's current Enterprise Value is €2,988.9 Mil.
Laboratorios Farmaceuticos Rovi's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €181.2 Mil.
Laboratorios Farmaceuticos Rovi's current Enterprise Value is €2,988.9 Mil.
Laboratorios Farmaceuticos Rovi's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €114.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi Enterprise Value Related Terms
Laboratorios Farmaceuticos Rovi Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi Enterprise Value Chart
XMAD:ROVI vs ZTS, UTHR, VTRS: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Enterprise Value falls into.
Laboratorios Farmaceuticos Rovi Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of €2,988.9 Mil mean?
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) has a Enterprise Value of €2,988.9 Mil as of Jul. 01, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's Enterprise Value too high?
Laboratorios Farmaceuticos Rovi's current Enterprise Value is €2,988.9 Mil. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 97/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Enterprise Value compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Enterprise Value of €2,988.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Enterprise Value is €2,988.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (XMAD:ROVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €50.97, compared to a current price of €57.85 — trading 13.5% above its estimated fair value. The current Enterprise Value is €2,988.9 Mil. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (XMAD:ROVI), the current Enterprise Value is €2,988.9 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of €57.85 is trading 13.5% above its estimated GF Value™ of €50.97.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.
Key valuation signals for XMAD:ROVI:
Enterprise Value: €2,988.9 Mil
GF Value™: €50.97 vs. price of €57.85 (13.5% above fair value)
No single metric tells the full story. See the XMAD:ROVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
97GF Score
Get the complete analysis for XMAD:ROVI
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ROVI has been successfully added to your 
